CClinicalTrials.gg
RecruitingNCT03409263AUTIPSUpdated Nov 6, 2024

Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts

An observational study in Portal Hypertension, sponsored by Thomas Reiberger. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Thomas Reiberger · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
400
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Patients with TIPS will be recruited in this prospective registry study. The clinical course will be documented and biomarkers for prediction of complicatiosn will be assessed.

Read the detailed description

Patients with advanced chronic liver disease may develop portal hypertension, which is the main cause for most complications and deaths of patients with liver cirrhosis. Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) leads to instantaneous alleviation of portal hypertension, but may cause hepatic encephalopathy. Stent grafts, as well as patient stratification and medical surveillance, have drastically improved over the past decades. However, there are few data on long-term outcome after TIPS implantation.This prospective registry study will assess the clinical course of patients after undergoing TIPS intervention and biomarkers for complications after TIPS implantation.

02

Conditions studied

  • Portal Hypertension

Browse trials for

Keywords

  • Cirrhosis
  • Advanced chronic liver disease
  • Ascites
  • Variceal hemorrhage
  • Transjugular intrahepatic portosystemic shunt
03

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Inpatients or outpatients who are scheduled for TIPS implantation, or who have recently undergone TIPS implantation and are visiting outpatienc clinics for control visits/surveillance

Inclusion criteria

  • Age 18-99 years
  • Portal hypertension
  • Anticipated or past implantation of a transjugular intrahepatic portosystemic shunt (TIPS)
  • Informed consent

Exclusion criteria

Exclusion Criteria:

  • Retraction of consent
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • OtherObservational study

    Not applicable (observational registry study)

05

What researchers measure

Primary outcomes

  1. Transplant-free survival

    Assessment of transplant-free survival after TIPS implantation

    Time frame: 0-10 years

Secondary outcomes

  1. Assessment of portalhypertensive complications

    Incidence of portalhypertensive complications

    Time frame: 0-10 years

  2. Assessment of hepatic encephalopathy

    Incidence of hepatic encephalopathy

    Time frame: 0-10 years

  3. Assessment of Patient Reported Quality of Life (SF36v2)

    Validated Questionnaire: SF36v2 pre TIPS and after TIPS. The SF36 consists of 36 items measuring 8 domains: physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health. The mental (MCS) and physical (PCS) component summary scores, as the main read-outs of the SF-36 form, can be regarded as physiological ('normal') when the calculated score lies between 45 and 55, because the results are normalized to a normal "reference" population assigned 50 points. Scores below 45 define worse-than-average physical (PCS) or mental (MCS) health, while scores above 55 indicate better-than-average physical (PCS) or mental (MCS) health, when compared to a normal population.

    Time frame: 0-10 years

  4. Assessment of Patient Reported Quality of Life (CLDQ)

    Validated Questionnaire CLDQ pre TIPS and after TIPS The CLDQ includes 29 items in the following domains: abdominal symptoms, fatigue, systemic symptoms, activity, emotional function and worry. The responses in the 29 CLDQ items, respectively, are recorded on scales ranging from in 1 ("none of the time") to 7 ("all of the time").

    Time frame: 0-10 years

06

Study locations

1 of 1 sites recruiting
  • Medical University of Vienna
    Vienna, 1090, Austria
    • Thomas Reiberger, M.D. · Contact · thomas.reiberger@meduniwien.ac.at · +43140400
    • Lukas Hartl, M.D. · Contact · lukas.a.hartl@meduniwien.ac.at · +43140400
    • Mattias Mandorfer, M.D., Ph.D. · Contact
    • Bernhard Scheiner, M.D. · Contact
    • Thomas Reiberger, M.D. · Contact
    • Theresa Bucsics, M.D. · Contact
    • Lukas Hartl, M.D. · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data may not be shared publicly due to local data safety regulations. Please contact the sponsor for more information.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03409263
Lead sponsor
Thomas Reiberger
Collaborators
Austrian Association of Gastroenterology and Hepatology
Responsible party
Thomas Reiberger (Univ. Prof. Priv.-Doz. Dr., Medical University of Vienna) — Sponsor-investigator
First posted
Jan 24, 2018
Start date
Mar 28, 2018
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 6, 2024

Study contacts

Thomas Reiberger, MD
Contact
thomas.reiberger@meduniwien.ac.at
+43140400 ext. 47440
Lukas Hartl, MD
Contact
lukas.a.hartl@meduniwien.ac.at
+43140400 ext. 65890
Thomas Reiberger, MD
principal investigator · Medical University of Vienna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion